Last updated: May 11, 2025
Sponsor: Attikon Hospital
Overall Status: Active - Recruiting
Phase
N/A
Condition
Diabetes Mellitus, Type 1
Diabetes Prevention
Diabetes Mellitus Types I And Ii
Treatment
Minimed 780G
Clinical Study ID
NCT06978387
TYPE 1_CROSS-SECTIONAL
Ages 12-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Clinical diagnosis of type 1 diabetes >1 year prior to consent date. Diagnosis oftype 1 diabetes is based on the investigator's judgment; C peptide level andantibody determinations are not required.
HbA1c < 12.5%
Age >7years at the initiation of the system
Patients with Minimed 780G
History of 3 clinic visits in the last year
Exclusion
Exclusion Criteria:
Diabetic Ketoacidosis in the 6 months prior to screening visits
Study Design
Total Participants: 90
Treatment Group(s): 1
Primary Treatment: Minimed 780G
Phase:
Study Start date:
January 15, 2025
Estimated Completion Date:
September 01, 2025
Study Description
Connect with a study center
Attikon University General Hospital
Chaidari, 124 62
GreeceActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.